Agenus reports first quarter 2024 results

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024. in a concurrent press release accompanying agenus' earnings announcement, a $100m royalty financing agreement between ligand and agenus was reported. this pivotal, minimally dilutive capital infusion will support the key development and launch readiness initiatives needed to advan.
AGEN Ratings Summary
AGEN Quant Ranking